BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26962160)

  • 1. Chemotherapy for Bone Sarcoma in Adults.
    Wagner MJ; Livingston JA; Patel SR; Benjamin RS
    J Oncol Pract; 2016 Mar; 12(3):208-16. PubMed ID: 26962160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for bone sarcomas in adults: the MD anderson experience.
    Benjamin RS; Wagner MJ; Livingston JA; Ravi V; Patel SR
    Am Soc Clin Oncol Educ Book; 2015; ():e656-60. PubMed ID: 25993237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of chemotherapy for patients with bone and soft-tissue sarcomas.
    Wesolowski R; Budd GT
    Cleve Clin J Med; 2010 Mar; 77 Suppl 1():S23-6. PubMed ID: 20179184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapeutic concepts for bone sarcomas].
    Kager L; Bielack S
    Unfallchirurg; 2014 Jun; 117(6):517-22. PubMed ID: 24903502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard chemotherapy for malignant bony tumors in children and young adults.
    Rafique A; Kent PM
    Curr Probl Cancer; 2013; 37(4):207-14. PubMed ID: 24238586
    [No Abstract]   [Full Text] [Related]  

  • 7. The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan.
    Nagano A; Tsugita M; Nishimoto Y; Akiyama H; Kawai A
    Jpn J Clin Oncol; 2021 Aug; 51(9):1430-1436. PubMed ID: 34105731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't?
    Carter SK
    J Clin Oncol; 1984 Mar; 2(3):147-8. PubMed ID: 6583329
    [No Abstract]   [Full Text] [Related]  

  • 9. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
    Saeter G; Wiebe T; Wiklund T; Monge O; Wahlqvist Y; Engström K; Forestier E; Holmström T; Stenwig AE; Willén H; Brosjö O; Follerås G; Alvegård TA; Strander H
    Acta Orthop Scand Suppl; 1999 Jun; 285():74-82. PubMed ID: 10429627
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in the Treatment of Pediatric Bone Sarcomas.
    Grohar PJ; Janeway KA; Mase LD; Schiffman JD
    Am Soc Clin Oncol Educ Book; 2017; 37():725-735. PubMed ID: 28561686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of malignant bone tumors].
    Höffken K; Seeber S; Gallmeier WM; Bruntsch U; Hossfeld DK; Schmidt CG
    Chirurg; 1977 Apr; 48(4):274-9. PubMed ID: 324726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
    Just MA; Van Mater D; Wagner LM
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29084. PubMed ID: 33894051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).
    Longhi A; Ferrari S; Tamburini A; Luksch R; Fagioli F; Bacci G; Ferrari C
    Cancer; 2012 Oct; 118(20):5050-9. PubMed ID: 22415578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of polychemotherapy in the management of malignant bone tumors].
    Reichardt P; Dörken B
    Chirurg; 2002 Dec; 73(12):1170-3. PubMed ID: 12491045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy in primary osteogenic sarcoma in patients over the age of forty.
    Ozkurt B; Basarir K; Yalcin B; Merter A; Yildiz Y; Saglik Y
    Acta Orthop Traumatol Turc; 2017 Mar; 51(2):123-127. PubMed ID: 28214261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience.
    Bruland ØS; Bauer H; Alvegaard T; Smeland S
    Cancer Treat Res; 2009; 152():309-18. PubMed ID: 20213398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts on the molecular biology of osteosarcoma.
    Gorlick R
    Cancer Treat Res; 2009; 152():467-78. PubMed ID: 20213409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.